Healio Rheumatology Current Issue
The following articles appeared in the print edition of Healio Rheumatology.
Table of Contents
- Collaborative Effort: Where We Stand With Imaging Modalities in Rheumatologic Diseases
-
- 5 Highly Accessed SLE Stories Include Microbiome, Role of Cytokines
- Eli Lilly Announces Positive End Result for Baricitinib RA Phase 3 Study
- FDA Approves Biosimilar to Infliximab
- Sarilumab Meets Primary Endpoint in Phase 3 Comparative Study With Adalimumab
- Rheumatology Practice Models for 2016: How 1 + 1 Can Equal 3 Leonard H. Calabrese, DO
- ANCA-associated Vasculitis: Crossdisciplinary Considerations to Optimize Patient Care
- FDA Issues Draft Guidance for Labeling of Biosimilars
- New Certification for Nurses With Specialization in Rheumatology May Help Fill Treatment Gaps
-
- Apremilast Relieved Psoriatic Arthritis Symptoms in Phase 3 Study
- Risk of Hepatitis B Reactivation Low in Patients with RA Treated with Rituximab
- Severe Fatigue May Be Prevalent Among Patients With Inflammatory Rheumatic Diseases
- Combo rheumatology, dermatology clinic linked with increased patient satisfaction
- Earlier intervention with TNF inhibitors seen as more cost-effective for patients with PsA
- Husni Discusses the Use of MRI, Detailed Patient History in the Identification of SpA
- Researchers identify cytokines in pathogenesis of cutaneous lupus erythematosus
- VIDEO: Looney Discusses Tolerance in Autoimmune Disease
-
- VIDEO: Rigby Discusses Oncology Therapies and Autoimmune Diseases
- VIDEO: Silverman Discusses Human Microbiome and Lupus
- Clinical Trial Approved in United Kingdom for Biosimilar to Rituximab for RA
- Gerilimzumab Seen as Potentially Affordable Treatment for Patients with RA
- Sandoz Attains European Rights to Biosimilar to Infliximab from Pfizer
- Survey: Physicians Expect to Prescribe More Biosimilars in the Next 3 Years